Cathepsin S (CTSS or EC 3.4.22.27) Market -Pipeline Review, H2 2017

“The Latest Research Report Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Cathepsin S Market

Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin S (CTSS or EC 3.4.22.27)-Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils. The molecules developed by companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 1, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Neuropathic Pain, Rheumatoid Arthritis, Alzheimer’s Disease, Autoimmune Disorders, Cancer Pain, Celiac Disease, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Crohn’s Disease (Regional Enteritis), Diabetic Retinopathy, Liver Fibrosis, Lupus Nephritis, Osteoarthritis, Pancreatic Cancer, Primary Biliary Cirrhosis, Sicca Syndrome (Sjogren) and Systemic Lupus Erythematosus.

Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/1339576

Furthermore, this report also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)

– The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339576/cathepsin-s-ctss-or-ec-342227-pipeline-review-h2-2017-market-research-reports.pdf

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cathepsin S (CTSS or EC 3.4.22.27)-Overview 6

Cathepsin S (CTSS or EC 3.4.22.27)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Have Any Query? Ask Our Expert @

https://www.marketresearchreports.biz/sample/enquiry/1339576

Cathepsin S (CTSS or EC 3.4.22.27)-Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 13

Assessment by Molecule Type 14

Cathepsin S (CTSS or EC 3.4.22.27)-Companies Involved in Therapeutics Development 16

Amura Holdings Ltd 16

F. Hoffmann-La Roche Ltd 16

Fusion Antibodies Ltd 16

Sanofi 17

Virobay Inc 17

Cathepsin S (CTSS or EC 3.4.22.27)-Drug Profiles 19

AM-3840-Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

AM-3876-Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Fsn-0503h-Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

RG-7625-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

RO-5461111-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

SAR-114137-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

VBY-129-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

VBY-285-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

VBY-50365-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

VBY-825-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net